CLRB חוב כולל להון Cellectar Biosciences, Inc.

This daily price chart for the total debt-to-equity ratio of Cellectar Biosciences (CLRB) captures the metric at 0.05. The business currently relies on external financing, as it lacks commercial products and its primary developments are awaiting registration. Strict licensing requirements and patent protection for radioactive isotopes ensure a high barrier to entry. However, drug transportation complexities and the risk of failed trials pose threats to stability.

Developing radiopharmaceuticals for oncology centers requires significant capital expenditures, which directly impacts the financial stability of Cellectar Biosciences (CLRB). By analyzing the capital structure ratio (total debt to equity), an investor assesses the proportion of debt financing relative to equity capital, determining the business's level of dependence on creditors and the risks of servicing obligations amid revenue volatility from insurance payments.